Cis-resveratrol glucuronidation kinetics in human and recombinant UGT1A sources

Xenobiotica

Volumn 40, Issue 2, 2010, Pages 102-108

  Iwuchukwu, O F ^a   Nagar, S ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Atypical kinetics; Cis resveratrol; Glucuronidation; Recombinant supersomes; Total resveratrol; Uridine diphosphate glucuronosyltransferases (UGTs)

Indexed keywords

4' O GLUCURONIDE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; RESVERATROL; RESVERATROL 3 O GLUCURONIDE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME KINETICS; GLUCURONIDATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME;

ANTIOXIDANTS; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MICROSOMES; RECOMBINANT PROTEINS; STILBENES;

EID: 75649107244     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903406754     Document Type: Article

References (25)

1. Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Merillon JM, Magdalou J, Sabolovic N. (2001). Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys 393(2):281-289
2. Bertelli AA, Giovannini L, Bernini W, Migliori M, Fregoni M, Bavaresco L, Bertelli A. (1996). Antiplatelet activity of cis-resveratrol. Drugs Under Exp Clin Res 22(2):61-63
3. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO. (2005). S-naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60(4):423-433
4. Brill SS, Furimsky AM, Ho MN, Furniss MJ, Li Y, Green AG, Bradford WW, Green CE, Kapetanovic IM, Iyer LV. (2006). Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms. J Pharm Pharmacol 58(4):469-479
5. Campos-Toimil M, Elies J, Alvarez E, Verde I, Orallo F. (2007). Effects of trans- and cis-resveratrol on Ca2+ handling in A7r5 vascular myocytes. Eur J Pharmacol 577(1-3):91-99
6. Cornish-Bowden A. (1995). Fundamentals of enzyme kinetics. London: Portland.
7. de Santi C, Pietrabissa A, Mosca F, Pacifici GM. (2000). Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 30(11):1047-1054 (Pubitemid 32099176)
8. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. (2000). In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28(5):560-566
9. Hutzler JM, Tracy TS. (2002). Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30(4):355-362
10. Iwuchukwu OF, Ajetunmobi J, Ung D, Nagar S. (2009). Characterizing the effects of common UGT1A6 and UGT1A1 polymorphisms on cis and trans resveratrol glucuronidation. Drug Metab Dispos 37(8):1726-1732
11. Iwuchukwu OF, Nagar S. (2008). Resveratrol (trans-resveratrol, 3,5,4″-trihydroxy-trans-stilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos 36(2):322-330
12. Jayatilake GS, Jayasuriya H, Lee ES, Koonchanok NM, Geahlen RL, Ashendel CL, McLaughlin JL, Chang CJ. (1993). Kinase inhibitors from Polygonum cuspidatum. J Natural Prod 56(10):1805-1810
13. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, Tracy TS. (1998). Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37(12):4137-4147
14. Leiro J, Alvarez E, Arranz JA, Laguna R, Uriarte E, Orallo F. (2004). Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leuk Biol 75(6):1156-1165
15. Meng X, Maliakal P, Lu H, Lee MJ, Yang CS. (2004). Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agricult Food Chem 52(4):935-942
16. Nagar S, Remmel R, Hebbel R, Zimmerman C. (2004). Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metab Disposit 32:98-104.
17. Orallo F. (2006). Comparative studies of the antioxidant effects of cisand trans-resveratrol. Curr Med Chem 13(1):87-98.
18. Sabolovic N, Humbert AC, Radominska-Pandya A, Magdalou J. (2006). Resveratrol is efficiently glucuronidated by UDPglucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm Drug Dispos 27(4):181-189
19. Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R et al.. (2001). Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2(1):17-36.
20. Soars MG, Ring BJ, Wrighton SA. (2003). The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31(6):762-767
21. Tukey R, Strassburg C. (2000). Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Ann Rev Pharmacol Toxicol 40:581-616.
22. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. (2004). Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32(4):413-423
23. Urpi-Sarda M, Zamora-Ros R, Lamuela-Raventos R, Cherubini A, Jauregui O, de la Torre R, Covas MI, Estruch R, Jaeger W, Andres-Lacueva C. (2007). HPLC-tandem mass spectrometric method to characterize resveratrol metabolism in humans. Clin Chem 53(2):292-299
24. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V, Marchelli R. (2005). Bioavailability of transresveratrol from red wine in humans. Mol Nutr Food Res 49(5):495-504.
25. Zhang H, Varlamova O, Vargas FM, Falany CN, Leyh TS. (1998). Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. J Biol Chem 273(18):10888-10892